Proteomic Analysis of Blood Plasma using High Throughput Sequencers

摘要 由DNA、RNA和其他经过化学修饰的核酸制成的适体可以被改造成 与血液中循环的蛋白质等生物分子紧密结合。 该项目的主要目标是开发一套适体试剂盒，以实现同时测量 对蛋白质丰度图谱的研究，特别是对血液中显著差异丰富的蛋白质的研究。这 将有助于癌症诊断和监测病程和治疗过程中的蛋白质群 干预。预期的产品是适体蛋白质组学试剂盒(AP-KIT)，研究人员和 临床医生全面描述健康人和癌症患者之间的差异。 这些试剂盒将在内部进行验证，并使用精心挑选的专注于前列腺癌的样本进行测试。 AP-Kit将为癌症科学家提供新的工具，从而突破对癌症的理解 并创造新的、更有效的治疗和预防方法。医生将能够诊断 更早地治疗肿瘤，减轻癌症患者的放疗和化疗负担。AP-化验 将帮助监测癌症治疗的进展，并允许为个人定制治疗 病人。这些结果将提高生活质量，大幅减轻癌症给社会带来的负担。

Abstract Aptamers made from DNA, RNA and other nucleic acids that have chemical modifications can be engineered to bind tightly to biomolecules like the proteins that circulate in blood. The primary goal of this project is to develop a kit of aptamer reagents to enable simultaneous measurement of protein abundance profiles, focusing especially on significant differentially abundant proteins in blood. This will aid in cancer diagnostics and in monitoring protein populations over the course of disease and therapeutic intervention. The intended product is an Aptamer Proteomics kit (AP-kit) that can be used by researchers and clinicians to comprehensively profile the differences between healthy individuals and those afflicted with cancer. The kits will be validated in-house and tested with carefully curated samples focused on prostate cancer. The AP-kits will give cancer scientists new tools that lead to breakthroughs in the understanding of cancer types and to create new and more effective treatments and preventions. Physicians will be enabled to diagnose tumors earlier, reducing the burden of radiation treatments and chemotherapy on cancer patients. AP-assays will aid in monitoring the progress of cancer therapies and allow treatments to be customized for individual patients. These outcomes will increase quality of life and substantially decrease the burden of cancer on society.